California Voters to Decide on Billions in Funding for Disease Research

2026-09-04 politics

Sacramento, Friday, 4 September 2026.
A coalition of over 50 advocacy groups supports California’s Proposition 38, an $8.4 billion research initiative that uniquely mandates returning 10% of future treatment royalties directly to the state.

Coalition Mobilizes for November 2026 Ballot Initiative

A broad coalition of over 50 patient advocacy, medical, and research organizations has officially endorsed California Proposition 38, marking a significant mobilization effort ahead of the November 2026 general election [1]. Known as the “Immunology Medical Research & Cures Initiative,” the measure seeks to authorize $8.4 billion in state bonds dedicated to immunology and immunotherapy research targeting conditions such as Parkinson’s, ALS, Alzheimer’s, cancer, and heart disease [2]. Key endorsers include The Michael J. Fox Foundation for Parkinson’s Research, the ALS Association, and the Association for Frontotemporal Degeneration, signaling strong institutional support for the proposed funding model [1]. Proponents argue that the initiative is imperative for accelerating research timelines, particularly for patients facing progressive neurodegenerative diseases where time is a critical factor [1].

The NAACP California Hawaii State Conference has also voiced support, emphasizing the potential for health equity improvements in disadvantaged communities disproportionately affected by diabetes, cancer, and heart disease [6]. Dr. Rick L. Callender, President of the NAACP California Hawaii State Conference, stated that the proposition represents an opportunity to provide hope by developing cures that have historically been out of reach for California’s disadvantaged communities [6]. This endorsement aligns with broader civil rights group support, including Equality California, which joined the coalition on September 1, 2026, citing the potential for immunology research to replicate the breakthroughs seen in HIV treatment [3]. The campaign aims to secure voter approval in the upcoming November 2026 election, positioning the state as a leader in medical research funding amidst federal uncertainties [1].

Funding Structure and Economic Implications

Proposition 38 proposes a distinct funding structure that splits resources equally, with 50% designated for competitive grants at California universities and nonprofits, and 50% allocated to a new nonprofit immunology institute affiliated with the University of California [1]. The measure mandates that 10% of all immunotherapy licensing proceeds be returned to the state to offset costs, alongside a requirement for a 20% discount on resulting cures for California patients [3]. While the principal bond amount is $8.4 billion, interest costs are projected to bring the total repayment obligation to $12 billion over the life of the bonds [4]. This represents a 42.857 increase in total cost when accounting for interest, a point of contention for critics concerned about fiscal efficiency [4].

Administrative safeguards include a 2% cap on state administrative expenses, mandatory public spending disclosure, and independent financial audits to ensure accountability [3]. However, critics argue that the financing mechanism is flawed compared to alternative legislative proposals, noting that only half of the funding is subject to competitive peer review [2]. The California Institute for Immunology and Immunotherapy (CIII) is the specific beneficiary of the non-competitive portion, having previously secured seed money from private donors and state allocations for a facility near UCLA [2]. Opponents suggest that a “No” vote reflects a rejection of this fragmented priority-setting approach rather than a rejection of science itself [4].

Legislative Context and Alternative Funding Measures

Parallel to Proposition 38, the California Legislature has advanced Senate Bill 895, a $7.5 billion bond measure for science research authored by State Senator Scott Wiener [5]. Unlike Proposition 38, SB 895 was delayed to the March 2028 presidential primary ballot after missing the June 2026 legislative deadline for the November 2026 election [2]. Governor Gavin Newsom is expected to sign SB 895, which aims to offset federal funding reductions following the suspension of over 1,000 California science grants by the Trump administration in 2025 [5]. The measure allocates funds broadly across biomedical research, wildfire prevention, and water supply, with oversight managed by a newly formed California Foundation for Science and Health Research Council [5].

State lawmakers sent the $7.5 billion measure to the Governor in late August 2026, framing it as a legislative resurrection of science funding efforts [7]. Senator Wiener noted the strategic decision to move the measure to 2028 to avoid ballot congestion with housing bonds and Proposition 38 [5]. While Proposition 38 focuses narrowly on immunology and specific diseases, SB 895 seeks to restore general research capacity lost to federal cuts, with the University of California system having received approximately $3 billion in federal research grants in the 2024-25 fiscal year [5]. Voters will ultimately decide between these distinct approaches to sustaining California’s position as the nation’s largest life sciences market [1].

Sources

Proposition 38 Biotech Research